Form 4: Redmile Group Converts Non-Voting Stock to Common Stock in IGM Biosciences

Redmile Group, a significant shareholder in IGM Biosciences, converted 113,400 shares of non-voting common stock into voting common stock on February 28, 2024.

Summary

• On February 28, 2024, Redmile Group, LLC converted 113,400 shares of IGM Biosciences' non-voting common stock into common stock.
• The conversion was executed at a price of $0.00 per share.
• Following the transaction, Redmile Group's beneficial ownership includes 3,089,062 shares of common stock and 7,199,325 derivative securities.
• Redmile Clients elected to increase the beneficial ownership percentage applicable to their shares from 4.99% to 10.95%, which increase became effective 61 days after the date of such election on December 4, 2023.
• Michael Lee, a managing director of Redmile, serves on the board of directors of IGM Biosciences.

Sentiment

Score: 6

Explanation: The document itself is neutral, reporting a transaction. The conversion and increased ownership could be interpreted as a slightly positive signal, but it's a routine filing.

Positives

• The conversion of non-voting stock to common stock could be seen as a positive signal, indicating Redmile's increased confidence in IGM Biosciences.
• Redmile increasing their beneficial ownership percentage from 4.99% to 10.95% shows a greater investment in the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.

Stakeholder Impact

• The conversion of stock and increased ownership may have a minor positive impact on shareholder confidence.

Key Dates